TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC boosted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 16.8% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 10,866 shares of the company’s stock after purchasing an additional 1,559 shares during the period. Los Angeles Capital Management LLC’s holdings in TransMedics Group were worth $1,706,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Vaughan Nelson Investment Management L.P. acquired a new position in TransMedics Group in the second quarter valued at approximately $39,862,000. Driehaus Capital Management LLC increased its holdings in shares of TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares during the period. Hood River Capital Management LLC purchased a new stake in TransMedics Group during the second quarter worth $18,854,000. Finally, Canada Pension Plan Investment Board acquired a new stake in TransMedics Group during the second quarter valued at $16,086,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Stephens upped their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Robert W. Baird lowered their price target on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Oppenheimer dropped their price objective on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 target price on shares of TransMedics Group in a research note on Tuesday, October 29th. Finally, Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $144.80.

Insiders Place Their Bets

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the sale, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,958 shares of company stock valued at $5,230,528. Insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $92.73 on Thursday. The firm has a 50-day simple moving average of $129.09 and a 200-day simple moving average of $139.89. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of 98.65 and a beta of 2.08. TransMedics Group, Inc. has a 52 week low of $61.98 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s revenue was up 63.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.12) EPS. On average, equities analysts predict that TransMedics Group, Inc. will post 1.07 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.